Abstract
Recently a possible cross talk about the relationship between p53 and beta-catenin has been suggested by the observation that colorectal cancers accumulating beta-catenin (as a result of APC mutations) also exhibit high frequency p53 mutations. Our aim was to evaluate the pattern of both the proteins and match these with the morphological changes in colorectal carcinogenesis. Immunohistochemical patterns of p53 and beta catenin were studied using the natural carcinogenetic model of malignant colorectal sporadic adenoma in 27 formalin-fixed paraffinembedded polyps. We found a progressive increase of p53 and beta-catenin staining from normal, to dysplastic, and to cancerous epithelium. We noted, in dysplastic and cancerous epithelium, but not in normal tissue, the translocation of beta-catenin from the cytoplasm to the nucleus, and in dysplastic epithelium, a significant correlation between p53 over expression and betacatenin patterns. Beta-catenin cytoplasmic accumulation seemed to drive p53 over expression already in the early stages of carcinogenesis, while nuclear beta-catenin translocation appeared to be related to a pattern of invasion of neoplastic cells.
Keywords: colorectal adenoma, immunohistochemistry, p53, beta-catenin
Current Pharmaceutical Design
Title: P53 and Beta-Catenin in Colorectal Cancer Progression
Volume: 9 Issue: 24
Author(s): Anna Maria Valentini, Michele Pirrelli, Letizia Renna, Raffaele Armentano and Maria Lucia Caruso
Affiliation:
Keywords: colorectal adenoma, immunohistochemistry, p53, beta-catenin
Abstract: Recently a possible cross talk about the relationship between p53 and beta-catenin has been suggested by the observation that colorectal cancers accumulating beta-catenin (as a result of APC mutations) also exhibit high frequency p53 mutations. Our aim was to evaluate the pattern of both the proteins and match these with the morphological changes in colorectal carcinogenesis. Immunohistochemical patterns of p53 and beta catenin were studied using the natural carcinogenetic model of malignant colorectal sporadic adenoma in 27 formalin-fixed paraffinembedded polyps. We found a progressive increase of p53 and beta-catenin staining from normal, to dysplastic, and to cancerous epithelium. We noted, in dysplastic and cancerous epithelium, but not in normal tissue, the translocation of beta-catenin from the cytoplasm to the nucleus, and in dysplastic epithelium, a significant correlation between p53 over expression and betacatenin patterns. Beta-catenin cytoplasmic accumulation seemed to drive p53 over expression already in the early stages of carcinogenesis, while nuclear beta-catenin translocation appeared to be related to a pattern of invasion of neoplastic cells.
Export Options
About this article
Cite this article as:
Valentini Maria Anna, Pirrelli Michele, Renna Letizia, Armentano Raffaele and Caruso Lucia Maria, P53 and Beta-Catenin in Colorectal Cancer Progression, Current Pharmaceutical Design 2003; 9 (24) . https://dx.doi.org/10.2174/1381612033454216
DOI https://dx.doi.org/10.2174/1381612033454216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer
Current Medicinal Chemistry The Urokinase Receptor Interactome
Current Pharmaceutical Design The Vitamin D Saga: Breaking Dawn
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Virtual Screening of Henna Compounds Library for Discovery of New Leads against Human Thymidine Phosphorylase, an Overexpressed Factor of Hand-Foot Syndrome
Letters in Drug Design & Discovery Modulators of the microRNA Biogenesis Pathway via Arrayed Lentiviral Enabled RNAi Screening for Drug and Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Synthesis and Cytotoxic Evaluation for Some New Dihydropyrimidinone Derivatives for Anticancer Activity
Letters in Drug Design & Discovery Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Role of CCK/Gastrin Receptors in Gastrointestinal/Metabolic Diseases and Results of Human Studies Using Gastrin/CCK Receptor Agonists/Antagonists in these Diseases
Current Topics in Medicinal Chemistry Application of Proteomics to the Discovery of Cancer Biomarkers
Current Cancer Therapy Reviews RPS24c Isoform Facilitates Tumor Angiogenesis <i>Via</i> Promoting the Stability of MVIH in Colorectal Cancer
Current Molecular Medicine β-Cyclodextrin Complexes of Hydrolyzable Adamantanoyl-IUdR Prodrugs - Radioiodination and Biodistribution in Mice Bearing Implanted KBALB Tumours
Current Radiopharmaceuticals Advancement in Microsphere Preparation Using Natural Polymers and Recent Patents
Recent Patents on Drug Delivery & Formulation The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Inulin as a Delivery Vehicle for Targeting Colon-Specific Cancer
Current Drug Delivery Pleiotropic Effects of Tocotrienols and Quercetin on Cellular Senescence: Introducing the Perspective of Senolytic Effects of Phytochemicals
Current Drug Targets The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR)
Medicinal Chemistry